


## PHARMACEUTICAL 2020

## Ra Pharmaceuticals Inc. Rank 43 of 358







## PHARMACEUTICAL 2020



## Ra Pharmaceuticals Inc. Rank 43 of 358

The relative strengths and weaknesses of Ra Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ra Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 104% points. The greatest weakness of Ra Pharmaceuticals Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 19% points.

The company's Economic Capital Ratio, given in the ranking table, is 227%, being 191% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	274,694
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	18,579
Liabilities, Non-Current	3,438
Other Assets	4,726
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	21
Other Net Income	4,291
Other Revenues	3,000
Property and Equipment	4,732
Research and Development	82,642
Selling, General and Administrative Expense	27,337

Output Variable	Value in 1000 USD
Assets	284,152
Liabilities	22,038
Expenses	109,979
Revenues	3,000
Stockholders Equity	262,114
Net Income	-102,688
Comprehensive Net Income	-102,688
Economic Capital Ratio	227%

